

Atrial Fibrillation Research Review™

Making Education Easy

Issue 46 - 2020

In this issue:

- > 4D flow for measuring atrial stasis during sinus rhythm in paroxysmal AF
- > Antibacterial envelopes for preventing infections with implanted CV electronic devices
- > Integrated management of AF in primary care
- > Rhythm control for AF with heart failure in the era of catheter ablation
- > Cost effectiveness of catheter ablation + LAA closure for AF with high stroke/bleeding risk
- > NOACs in very elderly East Asians with AF
- > AF screening by pharmacists during influenza vaccinations
- > Detecting AF with portable device during CV screening in primary care
- > Cryoballoon ablation in paroxysmal AF
- > Pulsed-field ablation in persistent AF
- > Internal (via ICD) vs. external cardioversion of AF

Abbreviations used in this issue:

AF = atrial fibrillation; **BMI** = body mass index; **CV** = cardiovascular;
EF = ejection fraction; **HR** = hazard ratio;
ICD = implantable cardioverter defibrillator; **ICH** = intracranial haemorrhage;
LA/LAA = left atrial (appendage); **LV** = left ventricular;
NOAC = nonvitamin K antagonist oral anticoagulant; **OR** = odds ratio;
PVI = pulmonary vein isolation.

Kindly Supported by



Welcome to issue 46 of Atrial Fibrillation Research Review.

This issue begins with research from Australia investigating whether atrial transit time is prolonged in patients with paroxysmal AF during sinus rhythm, consistent with underlying atrial stasis. Another team of Australian researchers have evaluated the cost effectiveness of combined catheter ablation and LAA closure, versus catheter ablation and standard oral anticoagulation, in patients with symptomatic AF.

With the importance of early AF detection in elderly patients increasing due to its increasing prevalence, another study selected for this issue, from the UK, offers hope that clinical pharmacists in primary care using a single-lead ECG were able to detect additional cases in elderly patients attending for influenza vaccinations. On a similar note, a portable AF screening device was also shown to be useful for detecting cases of AF among primary care patients referred for echocardiography.

I hope you enjoy this update in AF research, and I look forward to your comments and feedback.

Kind Regards,

Dr Andrei Catanchin

andrei.catanchin@researchreview.com.au

Measuring atrial stasis during sinus rhythm in patients with paroxysmal atrial fibrillation using 4 dimensional flow imaging

Authors: Costello BT et al.

Summary: These researchers used 4-dimensional flow imaging to determine if atrial transit time was prolonged in 91 patients with paroxysmal AF in sinus rhythm and 18 healthy sex-matched controls. They calculated residence time distributions of velocity fields by seeding virtual 'particles' at the right upper pulmonary vein, and then counting them as they left the mitral valve. Atrial stasis was expressed as RTD_{TC} , the derived constant of the residence time of particles in the left atrium, based on heartbeats. Compared with controls, patients with paroxysmal AF had higher RTD_{TC} values, indicative of greater atrial stasis (1.68 vs. 1.51 beats [$p=0.005$]), and patients with paroxysmal AF with CHA_2DS_2VASc scores ≥ 2 had greater atrial stasis with a greater median RDT_{TC} (1.72 vs. 1.52 [$p=0.03$]). Only female gender and LVEF were significant contributors to atrial RTD_{TC} (respective p values 0.006 and 0.023).

Comment: We know the higher stroke risk in AF patients applies even when in sinus rhythm, and there is often no clear temporal relationship between AF episodes and stroke/transient ischaemic attack events with anticoagulation decisions based on the CHA_2DS_2VASc score rather than AF burden or timing.

Reference: *Int J Cardiol* 2020;315:45–50

[Abstract](#)

Efficacy of antibacterial envelope in prevention of cardiovascular implantable electronic device infections in high-risk patients

Authors: Ullah W et al.

Summary: This was a systematic review and meta-analysis of six studies comparing patients with antibacterial enveloped ($n=5844$) versus conventional ($n=6053$) implanted CV electronic devices. Compared with the conventional devices, implantation of the antibacterial enveloped devices was associated with a lower likelihood of acquiring a major device infection (OR 0.34 [95% CI 0.13–0.86]); a propensity matched analysis revealed a consistent finding (0.29 [0.10–0.82]), as did stratified analyses according to retrospective versus prospective studies and follow-up durations of 6 vs. >6 months. A lower likelihood of mortality with antibacterial enveloped versus conventional devices did not achieve statistical significance (OR 0.55 [95% CI 0.16–1.91]).

Comment: While not strictly AF-related, this literature review supports the use of the antibacterial envelope for device insertion. Costs need to be considered before routine use is recommended, but there do not appear to be any related adverse events.

Reference: *Int J Cardiol* 2020;315:51–6

[Abstract](#)

RESEARCH REVIEW™ Australia's Leader in Specialist Publications

Integrated management of atrial fibrillation in primary care

Authors: van den Dries CJ et al.

Summary: Fifteen primary-care practices in the Netherlands were assigned to integrated care for AF (n=527) and 11 to usual care (n=713) in the randomised, open-label, pragmatic noninferiority ALL-IN trial; integrated care consisted of: i) quarterly AF check-ups by trained primary care nurses, focusing on possible interfering comorbidities; ii) anticoagulation therapy monitoring in primary care; and iii) easy access to cardiologist consultations and anticoagulation clinics. Compared with usual care, the integrated care intervention significantly reduced the 2-year all-cause mortality rate (primary endpoint; 3.5 vs 6.7 per 100 patient-years; adjusted HR 0.55 [95% CI 0.37–0.82]) and the 2-year non-CV-related mortality rate (adjusted HR 0.47 [0.27–0.82]), with no significant between-group difference for other adverse events.

Comment: The benefits of an 'AF clinic' approach go well beyond AF management, and in fact here the anticoagulation, ischaemic stroke and major bleeding were very similar between the two groups. And yet we see almost halving of all-cause mortality with an intervention that even in COVID times may be effectively delivered by phone. I'd strongly recommend reading the full paper (free online).

Reference: *Eur Heart J* 2020;41:2836–44

[Abstract](#)

Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation

Authors: Chen S et al.

Summary: A stratified pooled analysis of randomised data from 11 studies was undertaken to assess the efficacy and safety of antiarrhythmic drugs versus rate control (n=2486) or rhythm control using catheter ablation versus medical therapy (n=1112) for AF complicated by heart failure, with focus on hard clinical endpoints. No significant difference was seen between rhythm control with antiarrhythmics and medical rate control for all-cause mortality (OR 0.96 [p=0.65]) or stroke/thromboembolic events (0.91 [p=0.76]), but rhythm control with antiarrhythmics was associated with a significantly higher rate of rehospitalisation (1.25 [p=0.01]); however, compared with medical therapy, rhythm control via catheter ablation was associated with lower risks of death from any cause (0.51 [p=0.0003]), rehospitalisation (0.44 [p=0.003]) and arrhythmia recurrence (0.04 [p<0.00001]), no significant difference for stroke events (0.59 [p=0.27]), and greater improvements in LVEF (weighted mean difference, 6.8% [p=0.0004]) and quality of life (p=0.007).

Comment: Although a pooled analysis, these important results are highly compelling and strongly support catheter ablation for AF management in these complex patients. In this paper, antiarrhythmic drugs (e.g. amiodarone) were no more effective than simple rate control therapy but led to more re-admissions.

Reference: *Eur Heart J* 2020;41:2863–73

[Abstract](#)

Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk

Authors: Kawakami H et al.

Summary: These Australian researchers used a Markov model to assess the cost effectiveness of combined catheter ablation with LAA closure versus catheter ablation followed by standard oral anticoagulation for symptomatic AF. The base-case used a 10-year time horizon for a hypothetical cohort of 10,000 patients aged 65 years with symptomatic AF, a CHA₂DS₂-VASc score of 3 and a HAS-BLED score of 3. The respective total costs for the LAA closure and oral anticoagulation strategies were (US)\$29,027 and \$27,896, with the LAA closure strategy associated with 122 fewer disabling strokes and 203 fewer ICHs per 10,000 patients than the oral anticoagulation strategy, and an incremental cost-effectiveness ratio for the LAA closure strategy of \$11,072 per quality-adjusted life-year. Although cost effectiveness was highly dependent on ICH risk with the LAA closure strategy and the cost of the combined procedure in sensitivity analyses, LAA closure remained superior to the oral anticoagulation strategy under most circumstances. Scenario analyses revealed that combined catheter ablation and LAA closure was more cost effective in patients with higher stroke risk.

Comment: While this combined approach may be attractive, it's important to remember we don't yet have firm equivalence or superiority data for LAA closure versus continued NOAC therapy, and LA thrombus can originate from outside the appendage (and indeed from the closure device itself).

Reference: *Am Heart J*; Published online Aug 19, 2020

[Abstract](#)

Non-vitamin K antagonist oral anticoagulants in very elderly East Asians with atrial fibrillation

Authors: Kwon S et al.

Summary: This nationwide population-based study reported on the effectiveness and safety of NOACs (n=20,573) versus warfarin (n=4086) for Korean patients aged ≥80 years with AF; the two groups were balanced using inverse probability of treatment weighting. Compared with warfarin, NOAC use was associated with lower risks of ischaemic stroke (HR 0.739 [95% CI 0.617–0.892]) and a composite outcome of ischaemic stroke, major bleeding (including ICH) and gastrointestinal bleeding (0.783 [0.685–0.899]); there were also nonsignificant lower risks of gastrointestinal bleeding and major bleeding when assessed separately, whereas the ICH risk was similar. Apixaban and edoxaban were the NOACs associated with the greatest benefit for the composite outcome. Ischaemic stroke and the composite outcome were the only clinical outcomes for which a significant interaction was seen for age subgroups (80–89 years and ≥90 years, respective p values for interactions, 0.097 and 0.040).

Comment: Traditionally, this patient age group is poorly represented in large-scale trials and is at the highest risk of both ischaemic stroke and bleeding, even more so in the East Asian population where low dose NOACs are generally used. This study suggests NOACs are the preferred alternative in this population, in line with current AF guidelines for other age groups.

Reference: *Am Heart J* 2020;229:81–91

[Abstract](#)

Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during the influenza vaccination season

Authors: Savickas V et al.

Summary: This cross-sectional study assessed the feasibility of clinical pharmacists based in UK GP practices to screen for AF using digital technology and pulse palpation in individuals aged >65 years attending for influenza vaccination during the 2017–2018 and 2018–2019 seasons. Among 604 individuals screened, the AF prevalence was 4.3%. All those with AF qualified for anticoagulation, 57% were male and they were more likely to be older, have an increased BMI and have a CHA₂DS₂-VASc score ≥3. The respective sensitivity and specificity values for the clinical pharmacists diagnosing AF using pulse palpation were 76.9% and 92.2%, and the respective values using single-lead ECG were 88.5% and 97.2%. Four individuals were diagnosed with new AF at follow-up and three were started on anticoagulation. Single-lead ECG screening also helped detect other CV diagnoses, including LV hypertrophy, in 28 individuals. The screening strategy was deemed to be cost effective, and participant feedback was generally positive.

Comment: Influenza vaccination is free and strongly recommended in >65-year-old patients in Australia, even more so in the current SARS-CoV-2 climate, and the Kardia device is widely available, affordable and provides good quality ECG traces with generally accurate interpretation. This might serve as an ideal opportunity for AF screening in our society.

Reference: *PLoS Med* 2020;17:e1003197

[Abstract](#)



Atrial Fibrillation Research Review™

Independent commentary by Dr Andrei Catanchin,

a cardiologist/electrophysiologist specialising in the management of AF and other arrhythmias at Epworth HealthCare in Melbourne. He performs catheter ablation, implants pacemakers and ICDs (defibrillators) and his research interests include alternatives to warfarin (e.g. NOACs) in AF management. Dr Catanchin is a Senior Lecturer with the University of Melbourne, teaches at all levels and regularly presents at local and national meetings.

RESEARCH REVIEW™

Australia's Leader in Specialist Publications



Hypothetical patient.



XARELTO is approved for use in NVAF*, DVT or PE† patients with a CrCl as low as 15mL/min¹

*Prevention of stroke and systemic embolism in patients with NVAF and at least one additional risk factor for stroke. Please refer to the Xarelto PI for full list of indications.

†Treatment of DVT and PE and for the prevention of recurrent DVT and PE. Please refer to the Xarelto PI for full list of indications.



Contraindicated in CrCl <15mL/min. Use with caution in patients with CrCl = 15–29mL/min.
CrCl: Creatinine clearance; DVT: Deep vein thrombosis; NVAF: Non-valvular atrial fibrillation; OD: Once daily; PE: Pulmonary embolism.

PBS Information: Authority Required (STREAMLINED). Refer to PBS Schedule for full authority information.

PLEASE REVIEW THE FULL PRODUCT INFORMATION (PI) BEFORE PRESCRIBING. APPROVED PI AVAILABLE AT www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-01020-3&d=

Minimum Product Information. Xarelto® (rivaroxaban) INDICATIONS: Prevention of venous thromboembolism (VTE) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks); 10 mg tablet once daily. Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke; 20 mg tablet once daily (15 mg for patients with CrCl 15–49 mL/min). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent DVT and pulmonary embolism (PE); 15 mg tablet twice daily for 3 weeks, followed by 20 mg tablet once daily. Following completion of six to twelve months therapy, based on an individual assessment of the risk of recurrent DVT or PE against the risk for bleeding, dose reduction to 10 mg Xarelto once daily may be considered. In combination with aspirin, for the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD); 2.5 mg tablet twice daily in combination with 100 mg aspirin. Xarelto 15 mg and 20 mg tablets should be taken with food. Xarelto 2.5 mg and 10 mg may be taken with or without food. Tablets may be crushed and administered orally (mixed with water or applesauce) or given through gastric tubes. See full PI for details. **CONTRAINDICATIONS:** Hypersensitivity to rivaroxaban or to any of the excipients, clinically significant active bleeding, lesions at increased risk of clinically significant bleeding and patients with spontaneous impairment of haemostasis, significant hepatic disease which is associated with

coagulopathy, dialysis or severe renal impairment with a creatinine clearance < 15 mL/min, concomitant treatment with strong inhibitors of both CYP 3A4 and P-glycoprotein. Pregnancy, Lactation. **PRECAUTIONS:** Increased bleeding risk such as general haemorrhagic risk (see PI for list), bronchiectasis or history of pulmonary bleeding, renal impairment, hepatic impairment, surgery and interventions, spinal/epidural anaesthesia or puncture, patients with prosthetic heart valves (not recommended), patients with antiphospholipid syndrome, haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy, lactose intolerance. **INTERACTIONS WITH OTHER MEDICINES:** Care to be taken if concomitantly used with medicines affecting haemostasis; concomitant administration with NSAIDs, platelet aggregation inhibitors, Selective Serotonin Reuptake Inhibitors, Selective Norepinephrine Reuptake Inhibitors, other anticoagulants. **ADVERSE EFFECTS:** Please refer to PI for a complete list. Very common and common adverse reactions (≥ 1%) include post procedural haemorrhage, increased transaminases, gingival bleeding, constipation, diarrhoea, nausea, pyrexia, oedema peripheral, contusion, pain in extremity, headache, dizziness, haematuria, menorrhagia, epistaxis, haematoma, anaemia, rectal haemorrhage, fatigue and ecchymosis, haemoptysis, pruritus, conjunctival haemorrhage, abdominal pain, dyspepsia, gastrointestinal haemorrhage, syncope, hypotension, increased gamma-glutamyltransferase, tachycardia, vomiting, asthenia, wound haemorrhage, subcutaneous haematoma and rash. **DOSAGE AND ADMINISTRATION:** see INDICATIONS above. **BASED ON PI DATED:** 02 JUN 2020. **REFERENCE: 1.** XARELTO (rivaroxaban) Approved Product Information, 02 Jun 2020.



Bayer Australia Ltd. ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073. Xarelto® is a registered trademark of Bayer Group, Germany. PP-XAR-AU-0562-1. SSW. XAR-001443-00. July 2020.

Atrial fibrillation detection with a portable device during cardiovascular screening in primary care

Authors: Diamantino AC et al.

Summary: The performance of an AF screening device, which has a light indicator for rhythm irregularities and single-lead ECG, was evaluated in 1518 patients from primary care who had been referred for echocardiography. The participants held the device for 1 minute, and 12-lead ECG was performed for all patients positive for AF along with 250 who were negative. Complete echocardiograms were obtained for all high-risk patients and a sample of low-risk patients; intermediate-risk patients also initially underwent screening echocardiography with a complete study performed if an abnormality was suspected. The AF screening device returned a positive result for 6.4% of the participants, with 12.6% being high risk, 6.1% intermediate risk and 2.2% low risk, and a higher positivity rate in participants aged >65 vs. <65 years (9.3% vs. 4.8% [$p=0.001$]). An independent association was seen between AF screening device positivity and heart disease on echocardiography (OR 3.9 [95% CI 2.1–7.2]). Based on 12-lead ECG results, the respective sensitivity and specificity values for the AF screening device to detect AF were 90.2% and 84.0%.

Comment: Here we have another very quick and simple yet sophisticated and accurate device with potential utility in large-scale AF screening of at-risk patients presenting for another reason (e.g. while waiting for echocardiography).

Reference: *Heart* 2020;106:1261–6

[Abstract](#)

Cryoballoon ablation in patients with paroxysmal atrial fibrillation

Authors: Perego GB et al., on behalf of ClinicalService 1STOP project investigators

Summary: Acute procedural results and 1-year recurrence rates were reported for patients with paroxysmal AF who had undergone a single cryoballoon PVI procedure at Italian cardiology centres, comparing patients with ($n=282$) versus without ($n=1170$) structural heart disease. Compared with patients without structural heart disease, those with structural heart disease were older (mean age 62.9 vs 58.2 years [$p<0.001$]), were more likely to be male (79.1% vs. 69.8% [$p<0.002$]), were more likely to have a CHA₂DS₂VASc score ≥ 2 (63.4% vs. 40.2% [$p<0.001$]), had higher BMI (27.7 vs. 26.4 kg/m² [$p<0.001$]), had greater atrial diameter (43.8 vs. 40.2mm [$p<0.001$]) and had a lower LVEF (57.2 vs. 60.7% [$p<0.001$]). Nearly three-quarters of patients (73%) were receiving a class Ic or III antiarrhythmic drug at the time of ablation. There was no significant difference between the patients with versus without structural heart disease for procedure time (106.9 vs. 112.1 min [$p=0.248$]), fluoroscopic time (28.7 vs. 28.6 min [$p=0.819$]), complication rate (3.9% vs. 4.8% [$p=0.525$]) or freedom from symptom recurrence over 13.4 \pm 12.8 months of follow-up (78.0% vs. 78.4% [$p=0.895$]), but those with structural heart disease had a higher acute success rate (98.9% vs. 97.7% [$p=0.016$]). Recurrence rate was not related to LVEF or LA size. Among patients with structural heart disease, there was a decrease in the proportion receiving class Ic or III antiarrhythmic drugs from 70.7% pre-ablation to 28.7% after cryoballoon PVI ($p=0.001$).

Comment: The 78% 'success rate' at 12 months was seen in both groups (i.e. structural heart disease versus none) suggesting the important point is these were all paroxysmal AF patients (as opposed to persistent AF with more severe atrial substrate disease); the degree of comorbidity and structural heart disease was also relatively modest. Longer-term follow-up of both groups would be very interesting looking for progression.

Reference: *Heart Lung Circ* 2020;29:1078–86

[Abstract](#)

Pulsed field ablation in patients with persistent atrial fibrillation

Authors: Reddy VY et al.

Summary: Twenty-five patients with persistent AF underwent biphasic, bipolar pulsed-field ablation using a multispline catheter for PVI (96 pulmonary veins) and LA posterior wall ablation (24 patients) under intracardiac echocardiographic guidance in the single-arm PersAFOne study. The acute success rates for both procedures were 100% with the multispline pulsed-field ablation catheter alone. Acute cavotricuspid isthmus block was achieved using the focal pulsed-field ablation catheter in 13/13 patients. The median total procedure time was 125 minutes, including a median of 28 minutes for voltage mapping, with a median of 16 minutes for fluoroscopy. No postprocedural mucosal lesions or pulmonary vein narrowing was seen. Durable isolation (defined by entrance block) was evident in 96% of pulmonary veins and in 100% of LA posterior walls treated with the pentaspline catheter. Three patients had localised scar regression of the LA posterior wall ablation, albeit without conduction breakthrough.

Comment: This very exciting ablation modality made headlines owing to its very high tissue selectivity (i.e. transmural and effective atrial ablation without 'collateral damage' (e.g. oesophagus, phrenic nerve), rapidity and high efficacy for PVI. Here the authors extended the ablation beyond PVI, including more extensive substrate modification in persistent AF with similar results.

Reference: *J Am Coll Cardiol* 2020;76:1068–80

[Abstract](#)

Randomized trial comparing the effectiveness of internal (through implantable cardioverter defibrillator) versus external cardioversion of atrial fibrillation

Authors: Elayi CS et al.

Summary: Consecutive patients with a single-coil ICD who presented with symptomatic AF of <1 year duration (45.2% with nonischemic cardiomyopathies, mean EF 28.6% and 45.2% with biventricular ICDs) were randomised to maximum energy internal shock via their ICD ($n=16$) or an external direct current cardioversion at 200J using transcutaneous pads ($n=15$); crossover was permitted in the event success was not achieved with the first shock. Compared with the external cardioversion group, a significantly smaller proportion of the internal cardioversion group achieved conversion to sinus rhythm after a single shock (primary endpoint; 31.3% vs. 93.3% [$p<0.001$]), with all first failures achieving successful subsequent external cardioversion.

Comment: Although it may seem more attractive, simpler, more direct, possibly safer and theoretically more effective to use the implanted ICD lead and generator to cardiovert AF, in fact the reverse is true here. External pads can be positioned to deliver energy to the (likely enlarged) atria more directly; the anteroposterior orientation is recommended. Note these were all single coil leads (a lead with a superior vena cava coil and vectors programmed appropriately may have yielded different results).

Reference: *J Interv Card Electrophysiol* 2020;58:261–7

[Abstract](#)



Get your own copy of
**Atrial Fibrillation
RESEARCH REVIEW**

Become one of Research Review's
49,000 AU members

SIMPLY CLICK

I am a Health Professional

to send us an e-mail and we'll do the rest

Australian Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Research Reviews are prepared with an independent commentary from relevant specialists. To become a reviewer please email geoff@researchreview.com.au.

Research Review Australia Pty Ltd is an independent Australian publisher. Research Review receives funding from a variety of sources including Government depts., health product companies, insurers and other organisations with an interest in health. Journal content is created independently of sponsor companies with assistance from leading local specialists. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for Australian health professionals.

